Neoadjuvant chemotherapy and targeted therapy in breast cancer: Past, present, and future

Journal of Oncology

Volumn , Issue , 2013, Pages

  Gampenrieder, Simon P ^a   Rinnerthaler, Gabriel ^a   Greil, Richard ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; PERTUZUMAB; PREDNISOLONE; TRASTUZUMAB; VINCRISTINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE COURSE; DISEASE FREE INTERVAL; HUMAN; INFUSION RELATED REACTION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 84884226678     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2013/732047     Document Type: Review

References (63)

1. Rastogi R., Anderson S. J., Bear H. D., Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. Journal of Clinical Oncology 2008 26 16 2793 2-s2.0-51349161251 10.1200/JCO.2008.17.6883
2. Van der Hage J. A., Van de Velde C. J. H., Julien J.-P., Tubiana-Hulin M., Vandervelden C., Duchateau L., Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for research and Treatment of Cancer Trial 10902. Journal of Clinical Oncology 2001 19 22 4224 4237 2-s2.0-0035890633
3. Mauri D., Pavlidis N., Ioannidis J. P. A., Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. Journal of the National Cancer Institute 2005 97 3 188 194 2-s2.0-13744257860 10.1093/jnci/dji021
4. Greil R., The still long and winding road to neoadjuvant sytemic therapy as the standard of care in breast cancer. Breast Care 2006 1 6 352 357 2-s2.0-33845909298 10.1159/000098106
5. Hutcheon A. W., Heys S. D., Sarkar T. K., Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Research and Treatment 2003 82 supplement 1 S6
6. Cuppone F., Bria E., Carlini P., Milella M., Felici A., Sperduti I., Nisticò C., Terzoli E., Cognetti F., Giannarelli D., Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer 2008 113 2 238 246 2-s2.0-48249137272 10.1002/cncr.23544
7. Smith I. E., A'Hern R. P., Coombes G. A., Howell A., Ebbs S. R., Hickish T. F., O'Brien M. E. R., Mansi J. L., Wilson C. B., Robinson A. C., Murray P. A., Price C. G. A., Perren T. J., Laing R. W., Bliss J. M., A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Annals of Oncology 2004 15 5 751 758 2-s2.0-2642585065 10.1093/annonc/mdh175
8. Chua S., Smith I. E., A'Hern R. P., Coombes G. A., Hickish T. F., Robinson A. C., Laing R. W., O'Brien M. E. R., Ebbs S. R., Hong A., Wardley A., Mughal T., Verrill M., Dubois D., Bliss J. M., Allum W., Gui G., Dean S., Trask C., Kissin M., McKinna F., Goodman A., Howell T., Guilliford T., Golding A., McIllmurray M., Barrett J., Charlton C., Price C., Iveson T., O'Reilley S., Perren T., Mithal N., Ellis P., Allerton R., Bloomfield D., Agrawal R., Murray P., Pratt W., Davidson N., Mansi J., Rea D., Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/ cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Annals of Oncology 2005 16 9 1435 1441 2-s2.0-24044515003 10.1093/annonc/mdi276
9. Earl H. M., Vallier A., Hiller L., Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). Journal of Clinical Oncology 2009 27 supplement 15, abstract 522
10. Bear H. D., Tang G., Rastogi P., Bevacizumab added to neoadjuvant chemotherapy for breast cancer. The New England Journal of Medicine 2012 366 4 310 320 10.1056/NEJMoa1111097
11. G. Steger G., Greil R., Jakesz R., Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). Journal of Clinical Oncology 2010 28 supplement 15, abstract 530
12. Von Minckwitz G., Rezai M., Loibl S., Fasching P. A., Huober J., Tesch H., Bauerfeind I., Hilfrich J., Eidtmann H., Gerber B., Hanusch C., Kühn T., Du Bois A., Blohmer J.-U., Thomssen C., Dan Costa S., Jackisch C., Kaufmann M., Mehta K., Untch M., Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro Study. Journal of Clinical Oncology 2010 28 12 2015 2023 2-s2.0-77951629946 10.1200/JCO.2009.23.8303
13. Mieog J. S., van der Hage J. A., van de Velde C. J., Preoperative chemotherapy for women with operable breast cancer. Cochrane Database of Systematic Reviews 2007 2 CD005002 2-s2.0-34447336720
14. Mazouni C., Peintinger F., Wan-Kau S., Andre F., Gonzalez-Angulo A. M., Symmans W. F., Meric-Bernstam F., Valero V., Hortobagyi G. N., Pusztai L., Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. Journal of Clinical Oncology 2007 25 19 2650 2655 2-s2.0-34447577933 10.1200/JCO.2006.08.2271
15. von Minckwitz G., Untch M., Blohmer J. U., Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Journal of Clinical Oncology 2012 30 15 1796 1804 10.1200/JCO.2011.38.8595
16. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., Climent M. A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Baronio R., Feyereislova A., Barton C., Valagussa P., Baselga J., Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet 2010 375 9712 377 384 2-s2.0-75149145066 10.1016/S0140-6736(09)61964-4
17. Mlineritsch B., Tausch C., Singer C., Luschin-Ebengreuth G., Jakesz R., Ploner F., Stierer M., Melbinger E., Menzel C., Urbania A., Fridrik M., Steger G., Wohlmuth P., Gnant M., Greil R., Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Research and Treatment 2008 112 1 203 213 2-s2.0-52949128414 10.1007/s10549-007-9843-x
18. von Minckwitz G., Blohmer J. U., Costa S., Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients-results of the gepartrio trial. Cancer Research 2011 71 24, abstract S3-2 10.1158/0008-5472.SABCS11-S3-2
19. Huober J., Hanusch C., Fasching P. A., Neoadjuvant chemotherapy of paclitaxel with or without Rad001: results of the non-responder part of the GEPARQUINTO Study. Cancer Research 2011 71 24, absrtact 3-6 10.1158/0008-5472. SABCS11-S3-6
20. Kaufmann M., Eiermann W., Schuette M., Long-term results from the neoadjuvant GeparDuo trial: A randomized, multicenter, Open Phase III Study comparing a dose-intensified 8-week schedule of doxorubicin hydrochloride and docetaxel (ADoc) with a sequential 24-week schedule of doxorubicin hydrochloride/cyclophosphamide followed by docetaxel (AC-Doc) regimen as preoperative therapy (NACT) in patients (pts) with operable breast cancer. Journal of Clinical Oncology 2010 28 supplement 15, abstract 537
21. Ellis G. K., Barlow W. E., Gralow J. R., Hortobagyi G. N., Russell C. A., Royce M. E., Perez E. A., Lew D., Livingston R. B., Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. Journal of Clinical Oncology 2011 29 8 1014 1021 2-s2.0-79952771912 10.1200/JCO.2009.27. 6543
22. Untch M., Möbus V., Kuhn W., Muck B. R., Thomssen C., Bauerfeind I., Harbeck N., Werner C., Lebeau A., Schneeweiss A., Kahlert S., Von Koch F., Petry K. U., Wallwiener D., Kreienberg R., Albert U.-S., Lück H.-J., Hinke A., Jänicke F., Konecny G. E., Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. Journal of Clinical Oncology 2009 27 18 2938 2945 2-s2.0-67649921349 10.1200/JCO.2008.20.3133
23. Untch M., Fasching P. A., Konecny G. E., von Koch F., Conrad U., Fett W., Kurzeder C., Lück H.-J., Stickeler E., Urbaczyk H., Liedtke B., Salat C., Harbeck N., Müller V., Schmidt M., Hasmüller S., Lenhard M., Schuster T., Nekljudova V., Lebeau A., Loibl S., von Minckwitz G., PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer-results at the time of surgery. Annals of Oncology 2011 22 9 1988 1998 2-s2.0-80052414508 10.1093/annonc/mdq709
24. Untch M., von Minckwitz G., Konecny G. E., Conrad U., Fett W., Kurzeder C., Lück H.-J., Stickeler E., Urbaczyk H., Liedtke B., Beckmann M. W., Salat C., Harbeck N., Müller V., Schmidt M., Hasmüller S., Lenhard M., Nekljudova V., Lebeau A., Loibl S., Fasching P. A., PREPARE trial: a randomized phas III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Annals of Oncology 2011 22 9 1999 2006 2-s2.0-80052401850 10.1093/annonc/mdq713
25. Von Minckwitz G., Untch M., Nüesch E., Loibl S., Kaufmann M., Kümmel S., Fasching P. A., Eiermann W., Blohmer J.-U., Costa S. D., Mehta K., Hilfrich J., Jackisch C., Gerber B., Du Bois A., Huober J., Hanusch C., Konecny G., Fett W., Stickeler E., Harbeck N., Müller V., Jüni P., Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Research and Treatment 2011 125 1 145 156 2-s2.0-78651081149 10.1007/s10549-010-1228-x
26. Smith R. E., Bryant J., DeCillis A., Anderson S., Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. Journal of Clinical Oncology 2003 21 7 1195 1204 2-s2.0-0037837665 10.1200/JCO.2003.03.114
27. Karp J. E., Blackford A., Visvanathan K., Myelodysplatic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience. 2012, abstract 3-5 Proceedings of the San Antonio Breast Cancer Symposium 2012
28. Buzdar A. U., Ibrahim N. K., Francis D., Booser D. J., Thomas E. S., Theriault R. L., Pusztai L., Green M. C., Arun B. K., Giordano S. H., Cristofanilli M., Frye D. K., Smith T. L., Hunt K. K., Singletary S. E., Sahin A. A., Ewer M. S., Buchholz T. A., Berry D., Hortobagyi G. N., Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Journal of Clinical Oncology 2005 23 16 3676 3685 2-s2.0-20544460650 10.1200/JCO.2005.07.032
29. Untch M., Fasching P. A., Konecny G. E., Hasmuller S., Lebeau A., Kreienberg R., Camara O., Muller V., Du Bois A., Ku n T., Stickeler E., Harbeck N., Hoss C., Kahlert S., Beck T., Fett W., Mehta K. M., Von Minckwitz G., Loibl S., Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO Trial of the AGO and GBG Study Groups. Journal of Clinical Oncology 2011 29 25 3351 3357 2-s2.0-79957601951 10.1200/JCO.2010.31.4930
30. Untch M., Rezai M., Loibl S., Fasching P. A., Huober J., Tesch H., Bauerfeind I., Hilfrich J., Eidtmann H., Gerber B., Hanusch C., Kühn T., Du Bois A., Blohmer J.-U., Thomssen C., Dan Costa S., Jackisch C., Kaufmann M., Mehta K., Von Minckwitz G., Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro Study. Journal of Clinical Oncology 2010 28 12 2024 2031 2-s2.0-77951624086 10.1200/JCO.2009.23. 8451
31. Baselga J., Bradbury I., Eidtmann H., Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet 2012 379 9816 616 2-s2.0-84857211691 10.1016/S0140-6736(12)60268-2
32. Guarneri, V., Frassoldati A., Bottini A., Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. Journal of Clinical Oncology 2012 30 16 1989 1995 10.1200/JCO.2011.39. 0823
33. Robidoux A., Tang G., Rastogi P., Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. Journal of Clinical Oncology 2012 30, abstract LBA506
34. Untch M., Loibl S., Bischoff J., Eidtmann H., Kaufmann M., Blohmer J.-U., Hilfrich J., Strumberg D., Fasching P. A., Kreienberg R., Tesch H., Hanusch C., Gerber B., Rezai M., Jackisch C., Huober J., Kühn T., Nekljudova V., von Minckwitz G., Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. The Lancet Oncology 2012 13 2 135 144 2-s2.0-84856444501 10.1016/S1470-2045(11)70397-7
35. Gianni L., Pienkowski T., Im Y.-H., Roman L., Tseng L.-M., Liu M.-C., Lluch A., Staroslawska E., de la Haba-Rodriguez J., Im S.-A., Pedrini J. L., Poirier B., Morandi P., Semiglazov V., Srimuninnimit V., Bianchi G., Szado T., Ratnayake J., Ross G., Valagussa P., Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology 2012 13 1 25 32 2-s2.0-84855297353 10.1016/S1470-2045(11)70336-9
36. Schneeweiss A., Chia S., Hickish T., Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-Free standard regimen: A Randomized Phase II Study (TRYPHAENA). Cancer Research 2011 71 24 supplement 3, abstract S5-6 10.1158/0008-5472.SABCS11-S5-6
37. Von Minckwitz G., Eidtmann H., Rezai M., Fasching P. A., Tesch H., Eggemann H., Schrader I., Kittel K., Hanusch C., Kreienberg R., Solbach C., Gerber B., Jackisch C., Kunz G., Blohmer J.-U., Huober J., Hauschild M., Fehm T., Müller B. M., Denkert C., Loibl S., Nekljudova V., Untch M., Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. The New England Journal of Medicine 2012 366 4 299 309 2-s2.0-84856291930 10.1056/NEJMoa1111065
38. Dowsett M., Smith I. E., Ebbs S. R., Dixon J. M., Skene A., A'Hern R., Salter J., Detre S., Hills M., Walsh G., Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. Journal of the National Cancer Institute 2007 99 2 167 170 2-s2.0-33846965616 10.1093/jnci/djk020
39. Niraula S., Dowling R. J., Ennis M., Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Research and Treatment 2012 135 3 821 830 10.1007/s10549-012-2223-1
40. Mauriac L., MacGrogan G., Avril A., Durand M., Floquet A., Debled M., Dilhuydy J. M., Bonichon F., Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Annals of Oncology 1999 10 1 47 52 2-s2.0-0033058219 10.1023/A:1008337009350
41. Mauriac L., Durand M., Avril A., Dilhuydy J.-M., Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. results of a randomized trial in a single centre. Annals of Oncology 1991 2 5 347 354 2-s2.0-0025910589
42. Scholl S. M., Fourquet A., Asselain B., Pierga J. Y., Vilcoq J. R., Durad J. C., Dorval T., Palangie T., Jouve M., Beuzeboc P., Garcio-Giralt E., Salmon R. J., De la Rochefordiere A., Campana F., Pouillart P., Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. European Journal of Cancer A 1994 30 5 645 652 2-s2.0-0028357653 10.1016/0959-8049(94)90537-1
43. Broët P., Scholl S. M., De la Rochefordière A., Fourquet A., Moreau T., De Rycke Y., Asselain B., Pouillart P., Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Research and Treatment 1999 58 2 151 156 2-s2.0-0033428140 10.1023/A:1006339918798
44. Makris A., Powles T. J., Ashley S. E., Chang J., Hickish T., Tidy V. A., Nash A. G., Ford H. T., A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Annals of Oncology 1998 9 11 1179 1184 2-s2.0-0031743702 10.1023/A: 1008400706949
45. Powles T. J., Hickish T. F., Makris A., Ashley S. E., O'Brien M. E. R., Tidy V. A., Casey S., Nash A. G., Sacks N., Cosgrove D., MacVicar D., Fernando I., Ford H. T., Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. Journal of Clinical Oncology 1995 13 3 547 552 2-s2.0-0028941377
46. Fisher B., Bryant J., Wolmark N., Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology 1998 16 8 2672 2685
47. Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B., Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of the National Cancer Institute. Monographs 2001 30 96 102 2-s2.0-0035751675
48. Taucher S., Steger G. G., Jakesz R., Tausch C., Wette V., Schippinger W., Kwasny W., Reiner G., Greil R., Dubsky P., Poestlberger S., Tschmelitsch J., Samonigg H., Gnant M., The potential risk of neoadjuvant chemotherapy in breast cancer patients-results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). Breast Cancer Research and Treatment 2008 112 2 309 316 2-s2.0-53949085110 10.1007/s10549-007-9844-9
49. Heys S. D., Hutcheon A. W., Sarkar T. K., Ogston K. N., Miller I. D., Payne S., Smith I., Walker L. G., Eremin O., Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clinical Breast Cancer 2002 3 2 S69 S74 2-s2.0-0036814394
50. Smith I. C., Heys S. D., Hutcheon A. W., Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. Journal of Clinical Oncology 2002 20 6 1456 1466
51. Bear H. D., Anderson S., Brown A., Smith R., Mamounas E. P., Fisher B., Margolese R., Theoret H., Soran A., Lawrence Wickerham D., Wolmark N., The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology 2003 21 22 4165 4174 2-s2.0-0642347622 10.1200/JCO.2003.12.005
52. Bear H. D., Anderson S., Smith R. E., Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology 2006 24 13 2019 2027
53. Evans T. R. J., Yellowlees A., Foster E., Earl H., Cameron D. A., Hutcheon A. W., Coleman R. E., Perren T., Gallagher C. J., Quigley M., Crown J., Jones A. L., Highley M., Leonard R. C. F., Mansi J. L., Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group Study. Journal of Clinical Oncology 2005 23 13 2988 2995 2-s2.0-21144439271 10.1200/JCO.2005.06.156
54. Diéras V., Fumoleau P., Romieu G., Tubiana-Hulin M., Namer M., Mauriac L., Guastalla J.-P., Pujade-Lauraine E., Kerbrat P., Maillart P., Pénault-Llorca F., Buyse M., Pouillart P., Randomized Parallel Study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. Journal of Clinical Oncology 2004 22 24 4958 4965 2-s2.0-16644384267 10.1200/JCO.2004.02.122
55. von Minckwitz G., Blohmer J.-U., Raab G., Löhr A., Gerber B., Heinrich G., Eidtmann H., Kaufmann M., Hilfrich J., Jackisch C., Zuna I., Costa S. D., In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Annals of Oncology 2005 16 1 56 63 2-s2.0-19944426993 10.1093/annonc/mdi001
56. Von Minckwitz G., Kümmel S., Vogel P., Hanusch C., Eidtmann H., Hilfrich J., Gerber B., Huober J., Costa S. D., Jackisch C., Loibl S., Mehta K., Kaufmann M., Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. Journal of the National Cancer Institute 2008 100 8 552 562 2-s2.0-43149114454 10.1093/jnci/djn089
57. Von Minckwitz G., Kümmel S., Vogel P., Hanusch C., Eidtmann H., Hilfrich J., Gerber B., Huober J., Costa S. D., Jackisch C., Loibl S., Mehta K., Kaufmann M., Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: phase III randomized gepartrio trial. Journal of the National Cancer Institute 2008 100 8 542 551 2-s2.0-43149120682 10.1093/jnci/djn085
58. Von Minckwitz G., Müller B. M., Loibl S., Budczies J., Hanusch C., Darb-Esfahani S., Hilfrich J., Weiss E., Huober J., Blohmer J. U., Du Bois A., Zahm D.-M., Khandan F., Hoffmann G., Gerber B., Eidtmann H., Fend F., Dietel M., Mehta K., Denkert C., Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. Journal of Clinical Oncology 2011 29 16 2150 2157 2-s2.0-79957940705 10.1200/JCO.2010.31.9079
59. Von Minckwitz G., Raab G., Caputo A., Schütte M., Hilfrich J., Blohmer J. U., Gerber B., Costa S. D., Merkle E., Eidtmann H., Lampe D., Jackisch C., Du Bois A., Kaufmann M., Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. Journal of Clinical Oncology 2005 23 12 2676 2685 2-s2.0-21044454272 10.1200/JCO.2005.05.078
60. Mohamed D., Raab G., Schuette M., Dose-dense versus sequential adriamcycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2,M0)-primary endpoint analysis of the GEPARDUO-Study. Journal of Clinical Oncology 2002 21, abstract 168
61. Ellis G. K., Barlow W. E., Gralow J. R., Hortobagyi G. N., Russell C. A., Royce M. E., Perez E. A., Lew D., Livingston R. B., Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. Journal of Clinical Oncology 2011 29 8 1014 1021 2-s2.0-79952771912 10.1200/JCO.2009.27. 6543
62. Arun B. K., Dhinghra K., Valero V., Kau S.-W., Broglio K., Booser D., Guerra L., Yin G., Walters R., Sahin A., Ibrahim N., Buzdar A. U., Frye D., Sneige N., Strom E., Ross M., Theriault R. L., Vadhan-Raj S., Hortobagyi G. N., Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist 2011 16 11 1527 1534 2-s2.0-82355163145 10.1634/theoncologist.2011-0134
63. Baselga J., Bradbury I., Eidtmann H., First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, Neoadjuvant Study of lapatinib, trastuzumab, and their combination plus paclitaxel in Women with HER2-positive primary breast cancer. Cancer Research 2010 70 supplement 24, abstract S3-3 157 158 10.1158/0008-5472.SABCS10-S3-3